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The activity of protein phosphatase 1 (PP1), a serine-
threonine phosphatase that participates ubiquitously
in cellular signaling, is controlled by a wide variety of
regulatory proteins that interact with PP1 at an allo-
steric regulatory site that recognizes a ‘‘loose’’ con-
sensus sequence (usually designated asRVXF) found
in all such regulatory proteins. Peptides containing
the regulatory consensus sequence have been found
to recapitulate the binding and PP1 activity modula-
tion of the regulatory proteins, suggesting that it
might be possible to design small-molecule surro-
gates that activate PP1 rather than inhibiting it. This
prospect constitutes a largely unexplored way of
controlling signaling pathways that could be func-
tionally complementary to themuchmore extensively
explored stratagem of kinase inhibition. Based on
these principles, we have designed a microcystin
analog that activates PP1.
INTRODUCTION
Oneof themost pervasive regulatorymechanisms in nature is the
reversible phosphorylation of amino acid side chains (Ser, Thr,
Tyr) in proteins, a process mediated by kinase-induced phos-
phorylation and reversed by phosphatases (Cohen, 1997). By se-
lectively modifying the substrate proteins, kinases and phospha-
tases indirectly control the charge, solvation, and bonding ability
of domains in countless enzymes, receptors, and ion channels.
These selectivemodifications are in turn responsible for changes
in conformation, binding interactions, membrane permeability,
and solute gradients, among other effects. This chemically sim-
ple phosphorylation/dephosphorylation cycle thus constitutes
a major control element for more global processes such as gly-
cogen synthesis, cell division, gene regulation, neurotransmis-
sion, muscle contraction, and many other second messenger
and signal transduction pathways (Shenolikar and Nairn, 1991;
Cohen, 1990).
Not surprisingly, then, impaired PP1 or PP2A activity is impli-
cated in a large number of cellular malfunctions, including tumor-
igenesis (Li et al., 1996), inhibition of neuronal differentiation
(Tanaka et al., 1995), the accumulation of amyloid plaque (SuzukiChemistry & Biology 15,et al., 1994), and others (Nishikawa et al., 2001). Because ki-
nases and phosphatases have literally thousands of substrates,
it has been a formidable challenge to decipher these complex
pathways which are only recently beginning to be understood.
A structurally diverse group of natural toxins including okadaic
acid, calyculin,microcystin-LR, and tautomycin has played an in-
strumental role in the progress that has beenmade in this regard.
These compounds are thought to exert their cytotoxic effects by
inhibiting PP1 and PP2A, which dramatically increases the phos-
phorylation state of a variety of proteins within the cell and in turn
results in acute lethal effects or unregulated cellular proliferation.
As a group, these toxins inhibit most PPP gene family members
(i.e., PP1, PP2A, PP4–6) quite potently, but not PP2B/calcineurin,
PP7, the PPM gene family (e.g., PP2C), or the tyrosine phospha-
tases. As a result, they have assumed considerable importance
as phosphatase structure/activity probes and, more generally,
as tools for studying intracellular signaling pathways. For exam-
ple, themost studied member of this class, okadaic acid—which
inhibits PP2A approximately 100-fold more potently than PP1
and PP2C not at all—has been used to distinguish PP2A-
dependent processes from PP1 and PP2C activity (Dautzenberg
et al., 1993) and in combinationwith calyculin to demonstrate that
reduced synaptic strength in aging is dependent on PP1/2A
signaling pathways (Norris et al., 1998).
Additional examples abound, but nearly all of the studies in
this field have focused on inhibition induced by binding of small
molecules in the active sites of PP1 and PP2A. In the past few
years, however, some attention has shifted to an allosteric site
on PP1 that modulates its activity in vivo by interacting with a va-
riety of endogenous binding (regulatory) proteins. In fact, PP1 is
not generally found in cells as the free enzyme, but rather in the
form of heteromeric complexes with binding/regulatory proteins
that not only target PP1 to specific regions in the cell but at the
same time modulate its activity. The number of PP1 binding pro-
teins that has been identified is rapidly increasing; to date, more
than 100 mammalian forms are known, most of which are now
thought to be regulatory or targeting subunits (Bollen, 2001).
The activity of PP1 is also modulated by several cytosolic regu-
latory protein inhibitors (inhibitor 1 [I-1], phospho-DARPP, and
inhibitor 2 [I-2]) that bind and strongly inhibit any PP1 that is
not bound to targeting proteins. All evidence suggests that
PP1 associates with only one regulatory protein at a time, that
the interaction with each occurs at a specific regulatory site on
PP1 distinct from the active site, and that regulatory proteins
recognize the allosteric site with a ‘‘loose’’ RVXF consensus167–174, February 2008 ª2008 Elsevier Ltd All rights reserved 167
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Small-Molecule Activation of PP1sequence of (K/R/H/N/S-V/I/L-X-F/W/Y) (hereafter referred to as
RVXF for simplicity) common to all the binding proteins. This
specificity contrasts sharply with the lack of a discernable sub-
strate consensus sequence at the active site. Although the active
and regulatory sites are well separated on the PP1 surface (see
below), the aforementioned endogenous inhibitors (e.g., I-1)
contain an RVXF sequence near their N terminus and thus
occupy both sites in the binary (inhibited) complexes.
To elucidate the structural basis for the binding of regulatory
proteins to PP1 via this specific interaction, a consensus se-
quence-containing fragment corresponding to the amino acids
63–75 of the GM subunit (GM[63–75]) has been cocrystallized
with PP1 and the structure determined by X-ray crystallography
to 3.0 A˚ resolution (Egloff et al., 1997). The result shows that
residues 64–69 of the GM[63–75] peptide bind in an extended con-
formation to a hydrophobic cleft near the C-terminal region of
PP1 that is located on the opposite side of the PP1c active site
(Figure 1). The major interactions between the 13 amino acid
GM[63–75] peptide and PP1c reside in residues 64–69 (Arg-Arg-
Val-Ser-Phe-Ala = R-R-V-S-F-A) of the peptide, which clearly
contains the consensus sequence. Substitution of residues in
the GM[63–75] sequence with alanine has shown that the Val and
Phe residues are themost important, as either modification com-
pletely abolishes binding to PP1 (Egloff et al., 1997). In addition,
phosphorylation of the serine 67 residue also eliminates activity,
in the peptide as well as the parent binding protein. A similar
16-mer peptide fragment also derived from the GM regulatory
protein (SSGGRRVSFADNFGFH) exhibits a low nanomolar dis-
sociation constant (Kd = 25.5 nM), as determined in surface plas-
mon resonance studies of PP1 binding (To´th et al., 2000).
That there is a consensus sequence for binding to the alloste-
ric site is perhaps at first surprising, considering that the various
regulatory proteins that recognize this site with a single consen-
sus sequence confer a wide range of activities on the enzyme.
However, there appear to be additional regions adjacent to the
regulatory site of PP1 that interact with other domains in the
binding proteins, and it has been suggested that it is these addi-
tional binding interactions that allosterically modulate the activity
of the enzyme in a ‘‘combinatorial’’ fashion (Bollen, 2001). In ad-
dition, recent evidence shows that in some cases, regulatory
proteins make contacts not only in the regulatory site but also
in the active site itself, which serves to further tune the binding
selectivity of substrates (Terrak et al., 2004). It remains uncertain
to what extent the mechanism of substrate-specific modulation
of PP1 activity by regulatory proteins is controlled by this type of
direct ‘‘customization’’ of the active site versus more conven-
tional induced allosteric conformational changes resulting from
specific interactions exclusively in the regulatory site and the
associated adjacent combinatorial sites.
With these considerations in mind, we were intrigued by the
possibility of identifying smallmolecules thatmight similarlymod-
ulate PP1 activity by binding at the regulatory site rather than the
active site targeted by small-molecule inhibitors. The fact that
peptides (13–300 residues) that correspond to the regulatory pro-
tein binding domains bind to the regulatory site of PP1 is obvi-
ously a positive step in the search for small-molecule allosteric
modulators; however, the minimum size for binding peptides
had not been established nor were there any reports of small-
molecule ligands for this site. Finding small-molecule regulatory168 Chemistry & Biology 15, 167–174, February 2008 ª2008 Elsevierprotein surrogates that would activate PP1 rather than inhibit it
would be very exciting, constituting a possible new approach to
decreasing the overall phosphorylation state in cells and possibly
complementing thewell-knownantitumor activity of kinase inhib-
itors. Although a large number of obstacles obscure the exact
pathway to this ultimate goal, identifying small-molecule ligands
for the PP1 regulatory site is a necessary first step.
RESULTS
PP1 Activation by Very Short RVXF-Containing Peptides
In order to determine the minimum RVXF peptide length neces-
sary to retain significant binding affinity, we began with a series
of peptides (Table 1) with sequences drawn from consensus
sequence regions of common PP1 regulatory proteins. Peptide
analogs were synthesized in decreasing lengths from 13-mers
(the length of peptide employed in the X-ray structure work) to
hexa- and pentapeptides containing the consensus sequence
plus one or two of the flanking residues apparent in the X-ray
structure. A basic N-acylated RVSF tetrapeptide corresponding
to the consensus sequence alone was also synthesized. The
peptides were prepared by Fmoc solid-phase peptide synthesis
(SPPS) and purified by reverse-phase HPLC. Each of the syn-
thetic peptides was then tested for its effect on the activity of
PP1-catalyzed hydrolysis of a short phosphopeptide substrate
(K-R-pT-I-R-R) in a commercial malachite green colorimetric
phosphatase activity assay (see Figure 2 for a representative
plot).
All RVXF-containing peptides resulted in 200%–300% activa-
tion of PP1, and the narrowness of this window suggests that the
modulation is primarily a result of allosteric interactions within the
Figure 1. Regulatory Site on PP1
Illustration of the PP1 dephosphorylation active site and allosteric regulatory
binding pocket highlighted in green (bound to residues 65–68 of rabbit GM),
showing the consensus binding sequence motif, RVSF in this case, rendered
from the published X-ray structure (Egloff et al., 1997).Ltd All rights reserved
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Peptide Sequence of Residues Sequencea EC50 (mM) Activation (% Control)
Human GM 60–72 AcNH-TRRVSFADSFGFN-OH 1.8 284
Rabbit GM 63–75 AcNH-GRRVSFADNFGFN-OH 1.1 221
U5 64–76 AcNH-KKRVVFADMKGLS-OH 0.28 265
Splicing factor PSF 361–373 AcNH-QLRVRFATHAAAL-OH 2.4 180
Human muscle PFK 45–57 AcNH-GARVFFVHEGYQG-OH 8.6 234
Hexapeptide — AcNH-RRVSFA-OH 2.7 240
Pentapeptide — AcNH-RRVSF-OH 10.2 228
Tetrapeptide — AcNH-RVSF-NMe 4.5 205
Control peptide — NH2-GEQRKDVYVQLYL-OH — 0
Mutant hexapeptide — AcNH-RRVSAA-OH — 0
aPP1 assays were performed with the a isoform of the enzyme; structural comparison of the four PP1 isoforms indicates a high degree of homology
(98%). The notable divergence lies primarily in the N- and C-terminal ends, with little variation in the allosteric RVXF binding region of interest (Terrak
et al., 2004).RVXF binding site and not to additional binding interactions with
the aforementioned ‘‘combinatorial’’ sites adjacent to the RVXF
cleft. This observation is consistent with the inference from the
X-ray structure—based on the largely disordered state of the
bound 13-mer—that peptide residues farther removed from
the RVXF sequence might not be binding to explicit sites on
PP1 (although this certainly might not be true of the presumably
more ordered full-sized binding proteins themselves).
The range of potencies is somewhat broader, with EC50 values
ranging from approximately 300 nM to nearly 10 mM. The fact
that there is no clear correlation of peptide length with EC50 is
consistent, again, with the idea that the primary binding interac-
tions between peptide and protein are in the RVXF sequence
common to all active peptides. There are some additional vari-
ables that require further study. For example, the most potent
peptide, based on the sequence of the U5 binding protein, is
the only one with a valine residue as ‘‘X’’ in the consensus se-
quence and a lysine residue flanking the consensus sequence
at the N terminus. Presumably, either of these structural features
could contribute to the observed increased activity; these and
other variables are currently being explored. Nonetheless, the
data in Table 1 provide convincing evidence that peptides as
small as 4-mers are sufficiently potent to warrant further optimi-
zation. It is important to recognize that although the EC50 values
are determined based on activity screening, binding affinity does
not control the level of activation. In other words, very tight
binders could in principle activate, deactivate, or have no effect
on this type ofmodulation. Conversely, weaker binders could ac-
tivate (or deactivate) more strongly than higher-affinity peptides,
although obviously at higher concentrations. Note that although
binding affinity and activation are ‘‘uncoupled’’ for this type of
allosteric interaction, another mode of activation—competitive
deinhibition—is correlated with relative affinities, as discussed
in more detail below.
Further demonstration of the RVXF prerequisite for PP1 activa-
tion by these short peptides was achieved through the synthesis
and assay of a mutant hexapeptide (AcNH-RRVSAA-OH) in
which the phenylalanine of the consensus motif is replaced by
an alanine. The critical significance of the Phe residue in the
RVXF motif is clearly apparent in mutational studies in which
regulatory proteins are inactivated when F is replaced with AChemistry & Biology 15,(Egloff et al., 1997). The PP1/rabbit GM cocrystal structure clearly
shows the specific contact responsible: there is a p-stacking in-
teraction between this phenylalanine residue in the consensus
sequence and Phe293 of the PP1 allosteric binding site (Egloff
et al., 1997).
There is no reason tobelieve that this interactionshouldnot also
be critical in binding of peptide surrogates for regulatory proteins
and, in thecaseathand, thesynthetic ‘‘mutant’’ hexapeptide lack-
ing the phenylalanine indeed shows no activity. In a more general
control, a random 13 residue control peptide lacking the RVXF
motif entirely also was completely inactive, ruling out nonspecific
peptide activation. The observed PP1 activation by even the
shortest regulatory peptide sequence demonstrates that the tet-
rapeptide RVSF is sufficient for enzyme recognition and activa-
tion, and thus is an acceptable starting point for the design of
small-molecule surrogates of reasonable molecular weight.
Before exploring that issue, however, we sought further evi-
dence that the observed effects were indeed because of specific
binding and not another subtle unanticipated effect. One such
experiment was to test some of the peptides for their ability to
activate PP1 by deinhibition, which can occur by competitively
displacing the inhibitor phospho-DARPP from the regulatory
site, resulting in increased activity relative to that of the binary (in-
hibited) complex. Because other regulatory proteins and larger
peptides containing the RVXF sequence are known to activate
this inhibited form of PP1, analogous behavior by the short pep-
tides should be expected if they are binding specifically in the
regulatory site (Yang et al., 2000; Brady et al., 1997). It is also
possible that they displace by binding in the active site, but
that would simply replace one active site ligand for another and
thus not result in activation. In this experiment, varying concen-
trations of the hexapeptide activator (Table 1) were added to
solutions of PP1 partially inhibited by phospho-DARPP, and
the resultant enzyme activities were measured. The phospho-
DARPP concentration was held constant at its IC50 value
(25 nM in this assay), which would be expected to yield a PP1 ac-
tivity signal approximately 50% of the control. As predicted, in-
creasing the concentration of the activating peptide produced
an increase in PP1 activity from just under the expected 50%
to over 80% before unfavorable solubility issues intervened (Fig-
ure 3). These results indicate that theRVXFpeptide competitively167–174, February 2008 ª2008 Elsevier Ltd All rights reserved 169
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increasing the enzymatic activity relative to the inhibited form.
This evidence of PP1 activation by deinhibition provides strong
evidence that PP1 activation by RVXF-containing peptides is
modulated by binding specifically at the allosteric site.
Another explicit demonstration of specific binding to the regu-
latory site would be to observe no effect of RVXF peptides on the
activity of PP2A, a close homolog of PP1 that exhibits very similar
substrate preferences in the active site yet lacks the RVXF regu-
latory site entirely. Thus, the same hexapeptide was assayed for
activation of PP2A in a procedure otherwise identical to that
described above for all of the RVXF peptides. Significantly, these
activation assays of the hexapeptide against PP2A did not yield
an observable increase in enzyme activity, suggesting that the
RVXF binding site is necessary for enzyme activation. These
results, along with the deinhibition studies, provide additional
evidence supporting binding of the RVXF peptides at the alloste-
ric site as the principal mechanism of enzyme activation.
These studies show that the RVXF domain alone is sufficient to
induce a significant increase in enzyme activity through both
direct allosteric activation as well as competitive deinhibition,
at least with the test substrate chosen. We also find that the con-
sensus sequence itself, RVXF, represents the minimum required
for PP1 activation with reasonable potency. Establishing a mini-
mum peptide length prerequisite for PP1 activation provides
a foundation for the design of small-molecule activators as
biological probes and, potentially, pharmacological agents.
PP1 Activation by a Small-Molecule Mimic of RVXF
After establishing a short tetrapeptide sequence (RVSF) as the
minimum requirement for PP1 activation, we turned our focus
toward the development of a small-molecule mimic with compa-
rable binding and activation capacity. While initiating virtual
screening, de novo design, and other typical studies in search
Figure 2. Representative EC50 Plot
Graphical representation of PP1 activation by the tetrapeptide AcN-RVSF-
NHMe. The other RVXF-containing peptides gave similar plots with low micro-
molar EC50 values (Table 1). Error bars reflect the standard error of the mean
(SEM).170 Chemistry & Biology 15, 167–174, February 2008 ª2008 Elsevieof small-molecule surrogates for RVXF activators, a somewhat
paradoxical experimental observation turned our immediate at-
tention toward a very surprising target structure: the ‘‘Adda’’
aryl diene moiety that is characteristic of the microcystin natural
toxins well-known for their potent inhibition of PP1 and PP2A.
Our group has previously reported that highly truncated analogs
of the microcystins containing only the Adda moiety (shown as
the bold portion of microcystin-LR in Figure 4A) and one addi-
tional amino acid retain significant activity as inhibitors (Gulledge
et al., 2003a, 2003b); however, screening of a number of addi-
tional highly truncated analogs produced two (Figure 4A, top
right) that showed clear evidence of activation in their dose-re-
sponse curves, rather than the expected inhibition: EC50 values
were 200 and 1000 mM, respectively, in preliminary experi-
ments using the malachite green assay (a different assay with
p-nitrophenylphosphate as substrate showed similar activation
effects). Although the potencies were low, this serendipitous re-
sult nonetheless suggested that Adda might be a partial surro-
gate for the RVXF peptides, that is, activating by binding to the
regulatory site of PP1.We therefore crudely aligned the structures
of other Adda analogs, including some containing the contiguous
arginine residue present in the macrocyclic ring of microcystin-
LR, in order to build a ‘‘full’’ tetrapeptide surrogate displaying
most of the structural features of RVSF itself (Figure 4A). The re-
semblance was quite striking, particularly for the designed com-
pound 1 as shown, and clearly supported the idea that N-ace-
tyl-Arg-Adda analogs might indeed map well onto the bound
conformation of RVSF and, by implication, act as activators.
With this possibility in mind, various conformations of the
RVXF mimic 1 were docked manually into the allosteric binding
site and compared to the bound conformation of the rabbit GM
regulatory domain peptide (Figure 4B). The best fit is shown
with the analog (green) overlaying quite well with the peptide
(purple) in the PP1 allosteric site (yellow). In the overlay compar-
ison, the C-terminal phenylalanine side chain of the peptide cor-
responds to the benzyl group of the analog at one endwith theN-
terminal acetylated arginines superimposed at the other (note
that the Addamoiety in the analog has been rotated about the in-
dicated bond to amore phenylalanine-like conformer). The RVXF
Figure 3. Activation by Deinhibition
PP1 activity assay results for the hexapeptide RRVSFA showing that it re-
verses potent PP1 inhibition by phospho-DARPP (25 nM). Error bars reflect
the standard error of the mean (SEM).r Ltd All rights reserved
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log, whereas the s-trans-diene characteristic of the Adda frag-
ment mimics the trans-amide conformation found in the bound
peptide and provides a generic surrogate for the X residue.
This structural correspondence provided further encouragement
to explore Adda analogs as small-molecule PP1 activators.
With the additional support of these modeling studies, we set
out to prepare analog 1 in order to test the hypothesis that such
RVXF surrogates can act as effective PP1 activators. The synthe-
sis was initiated by generation of fragment 4 according to pub-
lished literature protocol (Figure 5) (Humphrey et al., 1996; Beatty
et al., 1992), which was then converted into the corresponding
Wittig salt 5 in quantitative yield (Beatty et al., 1992). Meanwhile,
commercially available N-Boc-valinol (2) was oxidized under
Swern conditions to the aldehyde 3 (95%), which in turn under-
went Wittig coupling with the phosphorane produced by treating
5 with freshly prepared lithium diisopropylamide (LDA) to gener-
Figure 4. Structural Comparison of RVSF
Peptide, Microcystin, and Analog 1
Molecular modeling studies were performed using
the INSIGHT II LUDI module. The Adda analog
(green) was manually overlayed onto the bound
conformation of the tetrapeptide fragment (purple)
in the regulatory site (yellow) of the GM/PP1 coc-
rystal structure (Egloff et al., 1997). The LUDI scor-
ing function was utilized to grossly estimate regu-
latory site binding compatibility, which yielded an
Adda analog binding score of 199, more than
20% greater than that of the tetrapeptide alone
(164).
(A) Side-by-side comparison of the structural sim-
ilarity between Adda in microcystin-LR, the RVXF
consensus sequence (purple), and the designed
small-molecule RVXF mimic, 1 (green).
(B) Overlay of the RVXF mimic 1 (green) with the
RVSF residues in the PP1/rabbit GM (13-mer) coc-
rystal structure at the allosteric PP1 binding site
(the +1 and 1 peptide residues, A and R respec-
tively, are omitted for clarity as well as the other
seven, which were disordered in the crystal).
ate the trans-diene 6 in 68% yield (Beatty
et al., 1992; Catalano et al., 2004). This
Boc-protected adduct was deprotected
with TFA and then subjected to amino
acid coupling with Fmoc-L-Arg(Pbf)-OH.
Fmoc deprotection with 20% piperidine
in DMF was then followed by acetylation
of the N-terminal amino group. Finally,
removal of the Pbf group was achieved
with TFA/DCM (1:1) and triisopropylsilane
(TIS) to give the target RVXF mimic 1 in
32% yield over five steps.
With the RVXF analog 1 in hand, the
stage was set for determining whether it
indeed mimics the activity as well as the
structure of the RVXF-containing pep-
tides themselves. The analog was there-
fore submitted to the identical PP1 color-
imetric assay as that described for the
peptides (Table 1). Gratifyingly, analog 1 does indeed recapitu-
late the activity of these peptides quite closely, resulting in en-
zyme activation of almost 200%with an EC50 of 2.0 mM(Figure 6).
These values indicate activation efficacy and potency, respec-
tively, that are comparable to the truncated regulatory peptides,
which are presumably mediated in both instances by interac-
tions between ligand and protein within the allosteric regulatory
site of PP1. It remains to be determined whether this analog (or
the short peptides for that matter) activates PP1 toward other
substrates. However, even if it does not, it would be expected
to activate PP1 by the alternative mechanism of deinhibition;
studies on the substrate dependence of activation efficacy as
a function of substrate are underway.
These studies provide, to our knowledge, the first example of
a small-molecule PP1 activator that modulates enzyme activity
similarly to the regulatory proteins, thereby providing a founda-
tion for future generations of small-molecule targets as potentialChemistry & Biology 15, 167–174, February 2008 ª2008 Elsevier Ltd All rights reserved 171
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activator is based on the well-known class of microcystin inhib-
itors, which are known to bind in the active site and not the reg-
ulatory site, makes this discovery all the more remarkable. Al-
though at present we should view the structural and functional
similarity between the Adda-containing substructure of a toxin
that binds in the active site and a peptide that binds in the allo-
steric site as coincidental, it is interesting to speculate whether
microcystin-LR itself might exert its toxic effects by binding to
both the regulatory and active sites (as a 2:1 complex) under
some circumstances, as do the endogenous inhibitors such as
I-1 (albeit as 1:1 complexes). However, either way, the discovery
of a small-molecule activator paves the way for the development
of other more potent analogs based on this initial lead structure,
as well as a novel tool for studies on the role of PP1 activity in cel-
lular function.
DISCUSSION
In previous studies of the specific binding interaction between
glycogen binding protein (GM) and PP1, sequences of amino
acids corresponding to the PP1 binding domain of GM were
found to retain significant (sometimes low nanomolar) PP1 bind-
ing affinity (Egloff et al., 1997). In addition to the similarities dis-
cussed above, regulatory protein fragments have also been re-
ported to allosterically activate PP1 in much the same way as
the full-length proteins, at least in one case in which the N-termi-
nal domain that occupies a part of the PP1 active site is retained
(To´th et al., 2000). Peptides corresponding to the PP1 binding
domains of these regulatory proteins thus can recapitulate the
action of the corresponding full-sized proteins in some ways.
In addition, however, RVXF peptides can activate PP1 by a dif-
ferent mechanism: competitively displacing inhibitory regulatory
proteins (such as I-1 and phospho-DARPP) from PP1, the result
of which is PP1 activation, reportedly of as much as 600% or
more (Johnson et al., 1996). There is a critical distinction be-
tween this type of displacement activation and the combinatorial
allosteric modulation by regulatory proteins discussed above.
One results from the deinhibition of inactivated PP1 by compet-
itively displacing the regulatory protein inhibitor (via adissociative
mechanism), whereas the other is true allosteric activation of free
Figure 5. Synthesis of the Small-Molecule
RVXF Mimic 1
The route developed to prepare analog 1 employs
commercially available Boc-valinol and the previ-
ously synthesized allylic bromide 4, which are cou-
pled in a Wittig reaction and deprotected to give 1.
See text for details.
PP1. Thus, binding by RVXF peptides re-
sults in an increase of activity for PP1
complexed with inibitor 1 or phospho-
DARPP (the normal, inactive form of cyto-
solic PP1) by, in effect, stripping it away
from the regulatory protein inhibitor with-
out simultaneously inactivating it. The
result is an increase in cytosolic PP1 ac-
tivity even if no allosteric modulation takes place. Indeed, just
such an enhancement of PP1 activity by several RVXF peptides
(such as M110[1–38] and GM[63–93]) had previously been demon-
strated in peptide-permeabilized smooth muscle cells (Gailly
et al., 1996).
It is important to keep both potential modes of activation in
mind because, as discussed above, allosteric modulation can
be either positive or negative, and is often substrate dependent.
Conversely, deinhibition of inactivated PP1 should only activate,
that is, raise the level of activity above the baseline of nearly zero
by displacing the endogenous inhibitors. It has been shown in
other previous phosphatase activation studies that truncated
regulatory proteins can confer a direct increase of over 250%
in enzyme activity via direct allosteric activation toward the
phosphorylase a substrate (To´th et al., 2000; Johnson et al.,
1996). In that case, the truncated activating peptide consisted
of 38 residues that include two of the three functional domains
which make contacts with PP1: the N-terminal arm (which binds
partially in the active site) and the RVXF consensus motif.
As one would expect, similar peptides lacking the critical
RVXF domain result in a complete absence of allosteric site bind-
ing and enzyme activation (To´th et al., 2000; Johnson et al.,
1996). Additionally, however, in one report, an RVXF-containing
peptide lacking the N-terminal arm also resulted in little or no en-
zyme activation, at least with phosphorylase a as substrate
(Bollen, 2001; To´th et al., 2000). Because PP1 activation is sub-
strate dependent, it is possible that for the large phosphorylase
a substrate an extension of the catalytic cleft is necessary to en-
hance substrate binding and confer an observable increase in
enzyme activation. However, from this single example, it was
not clear whether theN-terminal domain is required for activation
generally, or for this substrate specifically.
Either way, the potential for this type of dual-mode activation
has not escaped the notice of others in the field; for example,
Patricia Cohen has suggested that ‘‘PP1c binding peptides.
may be useful pharmacological probes with which to explore
the role of PP1 in cell regulation’’ (Johnson et al., 1996). We
agree, and further assert that small-molecule mimics of these
peptides, such as the one reported in this paper, might be
even more useful by possibly avoiding the well-known defi-
ciencies of peptides as drugs and cellular probes.172 Chemistry & Biology 15, 167–174, February 2008 ª2008 Elsevier Ltd All rights reserved
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Previous studies showed that regulatory proteins bind to an
allosteric site on PP1 with a ‘‘loose’’ RVXF consensus se-
quence and that peptides consisting of 13–300 amino acids
can recapitulate some of the properties of the parent binding
proteins, including relatively tight binding and modulation of
PP1 activity. Our results demonstrate that peptides as small
as four residues, corresponding to the consensus sequence
alone, are sufficient to achieve similar results even though
they make no additional contacts outside the regulatory
site binding cleft; the measured EC50 values for activation
among the RVXF peptides tested (4–13 amino acids) ranged
from 280 nM to 10mM. These findings are consistent with pre-
vious structural studies showing that the essential contacts
between PP1 and an RVXF-containing 13-mer peptide reside
predominantly within or directly adjacent to the regulatory
site binding pocket, as only the consensus tetrapeptide
(RVSF in that case) and the two adjacent residues are or-
dered in the crystal (Egloff et al., 1997). Notably, the binding
of all peptides tested in our experiments, including the tetra-
peptide, result in 2- to 3-fold allosteric activation of enzyme
activity toward a phosphopeptide substrate. All experiments
conducted in these studies are consistent with allosteric site
binding as the principal mechanism of enzyme activation by
these small RVXF-containing peptides.
These studies of very short RVXF peptides, in conjunction
with a serendipitous experimental result in our related stud-
ies of microcystin-based inhibitors, led directly to the dis-
covery of a small-molecule RVXF mimic based on the Adda
substructure of microcystin-LR. Remarkably, this analog—
in direct contrast to its strongly inhibiting progenitor micro-
cystin-LR—binds at the PP1 regulatory site with similar
Figure 6. Activation of PP1 by Small-Molecule RVXF Mimic 1
Graphical representation of the standard PP1 activity assay in the presence of
increasing concentrations of the RVSF mimic 1. Error bars reflect the standard
error of the mean (SEM).Chemistry & Biology 15,affinity as the peptides while positively modulating PP1
activity by 200% toward the phosphopeptide substrate. This
compound thus provides an exciting new lead for small
nonpeptidic phosphatase activators potentially capable of
complementing the activity of protein kinase inhibitors.
EXPERIMENTAL PROCEDURES
Peptide Synthesis
Truncated regulatory proteins were synthesized by standard solid-phase
Fmoc chemistry on Wang resin. Peptides were then purified (>97%) and
analyzed on a reverse-phase HPLC/MS C18 preparative column.
(1-Isopropyl-7-Methoxy-4,6-Dimethyl-8-Phenyl-Octa-2,4-Dienyl)-
Carbamic Acid Tert-Butyl Ester (6)
Wittig salt 5 (1.003 g, 1.80 mmol) was suspended in 13 ml THF in a dry 50 ml
round bottom flask with a stirring bar and cooled to 0C under N2 while stirring.
Freshly prepared LDA (1.66 ml of a 1.04 M solution in THF, 1.72 mmol) was
added dropwise. After stirring for 10 min, aldehyde 3 (0.33 g, 1.64 mmol) was
dissolved in 5ml THF and added slowly to themixture. The reaction was stirred
an additional 45min at 0Cand then partitioned between 15ml water and 15ml
ethyl acetate followed by washings with water and brine. The aqueous layer
was back extracted once with 10 ml ethyl acetate. The combined organics
were dried over Na2SO4, filtered, and concentrated to a crude yellow liquid
which was further purified by silica gel chromatography (0%–5% ethyl acetate
in hexanes) to provide 0.58 g (88%) of the trans-dieneWittig adduct 6 as a pure
yellow oil: Rf 0.24 (1:9 ethyl acetate:hexanes);
1H NMR (500 MHz, CD3OD)
d 0.88 (t, J = 4.2 Hz, 6H), 1.02 (d, J = 5.4, 3H), 1.45 (s, 9H), 1.55 (s, 3H), 2.59
(dt, J = 9.8, 6.6 Hz, 1H), 2.68 (dd, J = 7.4, 6.6 Hz, 1H), 2.81 (dd, J = 4.6, 14.0
Hz, 2H), 3.18 (m, 1H), 3.24 (s, 3H), 4.03 (bs, 1H), 4.50 (bs, 1H), 5.36 (d, J =
10.0, 1H), 5.42 (dd, J = 6.7, 15.7 Hz, 1H), 6.15 (d, J = 15.7, 1H), 7.22 (m, 5H);
13C NMR (400 MHz, CDCl3) d 13.0, 16.5, 18.5, 19.0, 28.7, 29.9, 33.2, 36.9,
38.5, 57.9, 58.9, 79.3, 87.3, 126.2, 128.4, 129.7, 132.9, 135.4, 135.9, 139.7;




trans-diene 6 (0.024 g, 0.059 mmol) was dissolved in 0.5 ml DCM to which was
added 0.05 ml TFA and 0.010 ml TIS. The solution was stirred 45 min at room
temperature and then concentrated en vacuo with hexanes to yield the unpro-
tected free amine adduct of 6 which was carried forward without further puri-
fication. The TFA salt of 6 was then dissolved in 0.5 ml DMF to which was
added collidine (0.08 ml, 0.59 mmol) and a premixed solution of 1-hydroxy-
7-aza-benzotriazole uronium tetrafluoroborate (0.045 g, 0.12 mmol) and
Fmoc-Arg(Pbf)-OH (0.08 g, 0.12 mmol) in 0.25 ml DCM. The solution was
stirred at RT for 24 hr and then concentrated to a yellow oil which was filtered
through silica (5% isopropanol, 75% hexanes, 20% ethyl acetate) to a yellow
oil. The semicrude Fmoc compound was deprotected with a 20% piperidine in
DMF solution (0.25 ml) at RT for 30 min. The solution was then concentrated to
a light yellow oil to whichwas added a 20%solution of acetic anhydride in DMF
(0.25ml) and diisopropylethylamine (0.01ml). Themixture was stirred 30min at
RT and then concentrated en vacuo to give a crude yellow oil which was puri-
fied by reverse-phase HPLC (3:7 MeCN:0.1% aqueous TFA) to afford 9 mg
(31%) of pure white powder 1: 1H NMR (400 MHz, CD3OD) d 0.92 (d, J = 6.7
Hz, 6H), 1.02 (d, J = 7.0 Hz, 3H), 1.62 (s, 3H), 1.70 (m, 2H), 1.71 (m, 1H), 1.81
(m, 2H), 2.00 (s, 3H), 2.60 (m, 1H), 2.67 (dd, J = 7.5, 14.0 Hz, 1H), 2.82 (dd,
J = 4.6, 13.9 Hz, 1H), 3.22 (m, 1H), 3.23 (s, 3H), 3.31 (s, 2H), 4.18 (q, J = 7.0
Hz, IH), 4.40 (d, J = 5.8 Hz, 1H), 5.40 (d, J = 9.9 Hz, 1H), 5.51 (dd, J = 7.1,
15.6 Hz, 1H), 6.17 (d, J = 15.7 Hz, 1H), 7.21 (m, 5H), 7.97 (d, J = 8.9 Hz, 1H);
13C NMR (500 MHz, CD3OD) d 11.5, 15.2, 17.8, 18.3, 21.1, 25.0, 29.1, 32.4,
36.2, 37.6, 40.6, 53.3, 57.3, 57.4, 87.1, 125.2, 127.8, 129.2, 132.6, 135.2,




PP1 enzymes were purchased through New England Biolabs and the DARPP
inhibitor was purchased through Calbiochem. All other assay reagents were
purchased through Upstate Biotechnology as an all-inclusive kit and were167–174, February 2008 ª2008 Elsevier Ltd All rights reserved 173
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Small-Molecule Activation of PP1run according to the included protocol. The enzyme dilution buffer was com-
posed of 50 mM Tris-HCl (pH 7.0), 0.1 mM egtazic acid (EGTA), 0.1% b-mer-
captoethanol, and 1 mg/ml bovine serum albumin. The assay buffer consisted
of 50 mM Tris-HCl (pH 7.0) and 100 mMCaCl2. The malachite green solution A
consisted of 0.034%malachite green, 10 mM ammoniummolybdate, 1 N HCl,
and 3.4% ethanol. The malachite green additive solution B was purchased as
a 1% Tween 20 solution. A PP1 concentration of 1.7 U/ml (final concentration)
was used in the assays, with 1 U (unit) defined as the amount of enzyme
required to hydrolyze 1 nmol of p-nitrophenylphosphate (50 nM) in 1 min at
30C in a total reaction volume of 50 ml. Supplied phosphate-free water was
used toprepare all aqueous solutions. Enzymedilution bufferwas used to dilute
the PP1 enzyme. The malachite green phosphate detection solution was pre-
pared by the addition of 1 ml solution A to each 10 ml of solution B (100 ml of
the mixed AB solution was used per assay well).
Malachite Green PP1 Activity Assays
Assay reactions were carried out by the addition of 20 ml assay buffer, 20 ml
aqueous diluted peptide (0.01–100 mM concentrations), and 10 ml diluted re-
combinant enzyme (in enzyme dilution buffer) to a 96-well PCR plate at 0C.
The reactions were then incubated at 30C for 5 min, followed immediately
by the addition of 10 ml of the aqueous diluted substrate (K-R-Tp-I-R-R), and
incubated again at 30C for 30 min. To each reaction was added 100 ml mala-
chite green solution (AB), and UV-vis readings were taken at 630 nmwith a mi-
croplate reader after a 15 min development period at RT. Each determination
was performed in triplicate. Negative controls (substituting 30 ml of water in
place of the peptide and substrate) as well as positive controls (substituting
20 ml of water for the peptide) accompanied each experiment. The results, after
subtracting out the negative control values, were plotted with a sigmoidal
curve fit program (XCEL Fit 4) in terms of percent activation relative to the pos-
itive control. Error bars (SEM) were added to reflect the precision between
triplicate measurements and EC50 values were calculated for each activator
(concentration at which peptide confers 50% of maximal activation).
DARPP Deinhibition Assays
Deinhibition assays were performed following the same activation protocol
mentioned above except that the 20 ml of assay buffer was replaced with
10 ml of assay buffer and 10 ml of DARPP solution (25 nM in assay buffer).
The phosphohexapeptide (K-R-Tp-I-R-R) was used as substrate and native
PP1 was used for enzyme.
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